Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.

Journal of the National Cancer Institute

Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M.
PMID: 33729494
J Natl Cancer Inst. 2021 Oct 01;113(10):1369-1378. doi: 10.1093/jnci/djab034.

BACKGROUND: There is a critical need to identify patient characteristics associated with long-term ovarian cancer survival.METHODS: Quality of life (QOL), measured by the Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index (FACT-O-TOI), including physical, functional, and ovarian-specific subscales, was compared...

Cite
Wenzel L, Osann K, McKinney C, et al. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst. 2021;113(10):1369-1378doi: 10.1093/jnci/djab034.
Wenzel, L., Osann, K., McKinney, C., Cella, D., Fulci, G., Scroggins, M. J., Lankes, H. A., Wang, V., Nephew, K. P., Maxwell, G. L., Mok, S. C., Conrads, T. P., Miller, A., Mannel, R. S., Gray, H. J., Hanjani, P., Huh, W. K., Spirtos, N., Leitao, M. M., Glaser, G., Sharma, S. K., Santin, A. D., Sperduto, P., Lele, S. B., Burger, R. A., Monk, B. J., & Birrer, M. (2021). Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal of the National Cancer Institute, 113(10), 1369-1378. https://doi.org/10.1093/jnci/djab034
Wenzel, Lari, et al. "Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival." Journal of the National Cancer Institute vol. 113,10 (2021): 1369-1378. doi: https://doi.org/10.1093/jnci/djab034
Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst. 2021 Oct 01;113(10):1369-1378. doi: 10.1093/jnci/djab034. PMID: 33729494; PMCID: PMC8486331.
Copy Download .nbib Format: NLM
Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea.

Journal of the National Cancer Institute

Ruddy KJ, Schaid DJ, Batzler A, Cecchini RS, Partridge AH, Norman A, Fehrenbacher L, Stewart EA, Trabuco E, Ginsburg E, Couch FJ, Fasching PA, Vachon C, Ganz PA.
PMID: 33159444
J Natl Cancer Inst. 2021 Aug 02;113(8):1105-1108. doi: 10.1093/jnci/djaa160.

Antimullerian hormone (AMH) is a promising biomarker for ovarian reserve. In this study, we assessed AMH before and 1 year after initiation of adjuvant chemotherapy on National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology B-47 in female participants...

Cite
Ruddy KJ, Schaid DJ, Batzler A, et al. Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. J Natl Cancer Inst. 2021;113(8):1105-1108doi: 10.1093/jnci/djaa160.
Ruddy, K. J., Schaid, D. J., Batzler, A., Cecchini, R. S., Partridge, A. H., Norman, A., Fehrenbacher, L., Stewart, E. A., Trabuco, E., Ginsburg, E., Couch, F. J., Fasching, P. A., Vachon, C., & Ganz, P. A. (2021). Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. Journal of the National Cancer Institute, 113(8), 1105-1108. https://doi.org/10.1093/jnci/djaa160
Ruddy, Kathryn J, et al. "Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea." Journal of the National Cancer Institute vol. 113,8 (2021): 1105-1108. doi: https://doi.org/10.1093/jnci/djaa160
Ruddy KJ, Schaid DJ, Batzler A, Cecchini RS, Partridge AH, Norman A, Fehrenbacher L, Stewart EA, Trabuco E, Ginsburg E, Couch FJ, Fasching PA, Vachon C, Ganz PA. Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. J Natl Cancer Inst. 2021 Aug 02;113(8):1105-1108. doi: 10.1093/jnci/djaa160. PMID: 33159444; PMCID: PMC8328977.
Copy Download .nbib Format: NLM
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

Lancet (London, England)

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.
PMID: 28801186
Lancet. 2017 Oct 07;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 08.

BACKGROUND: The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and...

Cite
van den Bent MJ, Baumert B, Erridge SC, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390(10103):1645-1653doi: 10.1016/S0140-6736(17)31442-3.
van den Bent, M. J., Baumert, B., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clement, P. M., Baurain, J. F., Mason, W. P., Wheeler, H., Chinot, O. L., Gill, S., Griffin, M., Brachman, D. G., Taal, W., Rudà, R., Weller, M., McBain, C., Reijneveld, J., Enting, R. H., Weber, D. C., Lesimple, T., Clenton, S., Gijtenbeek, A., Pascoe, S., Herrlinger, U., Hau, P., Dhermain, F., van Heuvel, I., Stupp, R., Aldape, K., Jenkins, R. B., Dubbink, H. J., Dinjens, W. N. M., Wesseling, P., Nuyens, S., Golfinopoulos, V., Gorlia, T., Wick, W., & Kros, J. M. (2017). Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet (London, England), 390(10103), 1645-1653. https://doi.org/10.1016/S0140-6736(17)31442-3
van den Bent, Martin J, et al. "Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study." Lancet (London, England) vol. 390,10103 (2017): 1645-1653. doi: https://doi.org/10.1016/S0140-6736(17)31442-3
van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017 Oct 07;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 08. PMID: 28801186; PMCID: PMC5806535.
Copy Download .nbib Format: NLM
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.

NPJ breast cancer

Geyer CE, Tang G, Mamounas EP, Rastogi P, Paik S, Shak S, Baehner FL, Crager M, Wickerham DL, Costantino JP, Wolmark N.
PMID: 30456299
NPJ Breast Cancer. 2018 Nov 14;4:37. doi: 10.1038/s41523-018-0090-6. eCollection 2018.

The NSABP B-20 prospective-retrospective study of the 21-gene Oncotype DX Breast Cancer Recurrence Score® test predicted benefit from addition of chemotherapy to tamoxifen in node-negative, estrogen-receptor positive breast cancer when recurrence score (RS) was ≥31. HER2 is a component...

Cite
Geyer CE, Tang G, Mamounas EP, et al. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer. 2018;4:37doi: 10.1038/s41523-018-0090-6.
Geyer, C. E., Tang, G., Mamounas, E. P., Rastogi, P., Paik, S., Shak, S., Baehner, F. L., Crager, M., Wickerham, D. L., Costantino, J. P., & Wolmark, N. (2018). 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ breast cancer, 437. https://doi.org/10.1038/s41523-018-0090-6
Geyer, Charles E, et al. "21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer." NPJ breast cancer vol. 4 (2018): 37. doi: https://doi.org/10.1038/s41523-018-0090-6
Geyer CE, Tang G, Mamounas EP, Rastogi P, Paik S, Shak S, Baehner FL, Crager M, Wickerham DL, Costantino JP, Wolmark N. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer. 2018 Nov 14;4:37. doi: 10.1038/s41523-018-0090-6. eCollection 2018. PMID: 30456299; PMCID: PMC6235896.
Copy Download .nbib Format: NLM
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831.

JNCI cancer spectrum

Pogue-Geile KL, Song N, Serie DJ, Wang Y, Gavin PG, Kim RS, Tanaka N, Fumagalli D, Taniyama Y, Li Z, Rastogi P, Swain SM, Mamounas EP, Geyer CE, Wolmark N, Lucas PC, Paik S, Thompson EA.
PMID: 33241186
JNCI Cancer Spectr. 2020 Sep 07;4(5):pkaa058. doi: 10.1093/jncics/pkaa058. eCollection 2020 Oct.

Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab to chemotherapy in the adjuvant setting for...

Cite
Pogue-Geile KL, Song N, Serie DJ, et al. Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831. JNCI Cancer Spectr. 2020;4(5):pkaa058doi: 10.1093/jncics/pkaa058.
Pogue-Geile, K. L., Song, N., Serie, D. J., Wang, Y., Gavin, P. G., Kim, R. S., Tanaka, N., Fumagalli, D., Taniyama, Y., Li, Z., Rastogi, P., Swain, S. M., Mamounas, E. P., Geyer, C. E., Wolmark, N., Lucas, P. C., Paik, S., & Thompson, E. A. (2020). Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831. JNCI cancer spectrum, 4(5), pkaa058. https://doi.org/10.1093/jncics/pkaa058
Pogue-Geile, Katherine L, et al. "Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831." JNCI cancer spectrum vol. 4,5 (2020): pkaa058. doi: https://doi.org/10.1093/jncics/pkaa058
Pogue-Geile KL, Song N, Serie DJ, Wang Y, Gavin PG, Kim RS, Tanaka N, Fumagalli D, Taniyama Y, Li Z, Rastogi P, Swain SM, Mamounas EP, Geyer CE, Wolmark N, Lucas PC, Paik S, Thompson EA. Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831. JNCI Cancer Spectr. 2020 Sep 07;4(5):pkaa058. doi: 10.1093/jncics/pkaa058. eCollection 2020 Oct. PMID: 33241186; PMCID: PMC7674704.
Copy Download .nbib Format: NLM
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.

Clinical cancer research : an official journal of the American Association for Cancer Research

Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK.
PMID: 33766814
Clin Cancer Res. 2021 May 15;27(10):2734-2741. doi: 10.1158/1078-0432.CCR-20-4618. Epub 2021 Mar 25.

PURPOSE: This surgical window of opportunity (window) study assessed the short-term effect of medroxyprogesterone acetate (MPA) alone versus MPA plus the histone deacetylase (HDAC) inhibitor entinostat on regulation of progesterone receptor (PR) in women with newly diagnosed endometrioid endometrial...

Cite
Duska LR, Filiaci VL, Walker JL, et al. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021;27(10):2734-2741doi: 10.1158/1078-0432.CCR-20-4618.
Duska, L. R., Filiaci, V. L., Walker, J. L., Holman, L. L., Hill, E. K., Moore, R. G., Ring, K. L., Pearl, M. L., Muller, C. Y., Kushnir, C. L., Lankes, H. A., Samuelson, M. I., Carrick, K. S., Rajan, A., Rodgers, W. H., Kohn, E. C., Piekarz, R., & Leslie, K. K. (2021). A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2734-2741. https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska, Linda R, et al. "A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2734-2741. doi: https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 May 15;27(10):2734-2741. doi: 10.1158/1078-0432.CCR-20-4618. Epub 2021 Mar 25. PMID: 33766814; PMCID: PMC8127359.
Copy Download .nbib Format: NLM
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.

Clinical cancer research : an official journal of the American Association for Cancer Research

Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK.
PMID: 33766814
Clin Cancer Res. 2021 May 15;27(10):2734-2741. doi: 10.1158/1078-0432.CCR-20-4618. Epub 2021 Mar 25.

PURPOSE: This surgical window of opportunity (window) study assessed the short-term effect of medroxyprogesterone acetate (MPA) alone versus MPA plus the histone deacetylase (HDAC) inhibitor entinostat on regulation of progesterone receptor (PR) in women with newly diagnosed endometrioid endometrial...

Cite
Duska LR, Filiaci VL, Walker JL, et al. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021;27(10):2734-2741doi: 10.1158/1078-0432.CCR-20-4618.
Duska, L. R., Filiaci, V. L., Walker, J. L., Holman, L. L., Hill, E. K., Moore, R. G., Ring, K. L., Pearl, M. L., Muller, C. Y., Kushnir, C. L., Lankes, H. A., Samuelson, M. I., Carrick, K. S., Rajan, A., Rodgers, W. H., Kohn, E. C., Piekarz, R., & Leslie, K. K. (2021). A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2734-2741. https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska, Linda R, et al. "A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2734-2741. doi: https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 May 15;27(10):2734-2741. doi: 10.1158/1078-0432.CCR-20-4618. Epub 2021 Mar 25. PMID: 33766814; PMCID: PMC8127359.
Copy Download .nbib Format: NLM
Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.

JAMA oncology

Mayadev JS, Enserro D, Lin YG, Da Silva DM, Lankes HA, Aghajanian C, Ghamande S, Moore KN, Kennedy VA, Fracasso PM, Schilder RJ.
PMID: 31774464
JAMA Oncol. 2020 Jan 01;6(1):92-99. doi: 10.1001/jamaoncol.2019.3857.

IMPORTANCE: Despite standard chemoradiotherapy (CRT), most women with lymph node (LN)-positive cervical cancer experience disease recurrence. Immunotherapy is being investigated in the up-front treatment setting.OBJECTIVES: To assess the safety of sequential immunotherapy after CRT and to investigate human papillomavirus...

Cite
Mayadev JS, Enserro D, Lin YG, et al. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncol. 2020;6(1):92-99doi: 10.1001/jamaoncol.2019.3857.
Mayadev, J. S., Enserro, D., Lin, Y. G., Da Silva, D. M., Lankes, H. A., Aghajanian, C., Ghamande, S., Moore, K. N., Kennedy, V. A., Fracasso, P. M., & Schilder, R. J. (2020). Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA oncology, 6(1), 92-99. https://doi.org/10.1001/jamaoncol.2019.3857
Mayadev, Jyoti S, et al. "Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer." JAMA oncology vol. 6,1 (2020): 92-99. doi: https://doi.org/10.1001/jamaoncol.2019.3857
Mayadev JS, Enserro D, Lin YG, Da Silva DM, Lankes HA, Aghajanian C, Ghamande S, Moore KN, Kennedy VA, Fracasso PM, Schilder RJ. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncol. 2020 Jan 01;6(1):92-99. doi: 10.1001/jamaoncol.2019.3857. PMID: 31774464; PMCID: PMC6902184.
Copy Download .nbib Format: NLM
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).

Gynecologic oncology reports

Santin AD, Filiaci V, Bellone S, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Frumovitz M, Khleif SN, Huh WK, Birrer MJ.
PMID: 31934607
Gynecol Oncol Rep. 2020 Jan 02;31:100532. doi: 10.1016/j.gore.2019.100532. eCollection 2020 Feb.

PURPOSE: NRG Oncology conducted a phase II trial to assess the antitumor activity and tolerability of copanlisib, a selective inhibitor of PIK3CA, in persistent or recurrent endometrial carcinoma harboring hotspot PIK3CA mutations.PATIENTS AND METHODS: Eligible patients had endometrial cancer...

Cite
Santin AD, Filiaci V, Bellone S, et al. Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecol Oncol Rep. 2020;31:100532doi: 10.1016/j.gore.2019.100532.
Santin, A. D., Filiaci, V., Bellone, S., Ratner, E. S., Mathews, C. A., Cantuaria, G., Gunderson, C. C., Rutledge, T., Buttin, B. M., Lankes, H. A., Frumovitz, M., Khleif, S. N., Huh, W. K., & Birrer, M. J. (2020). Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecologic oncology reports, 31100532. https://doi.org/10.1016/j.gore.2019.100532
Santin, Alessandro D, et al. "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)." Gynecologic oncology reports vol. 31 (2020): 100532. doi: https://doi.org/10.1016/j.gore.2019.100532
Santin AD, Filiaci V, Bellone S, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Frumovitz M, Khleif SN, Huh WK, Birrer MJ. Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecol Oncol Rep. 2020 Jan 02;31:100532. doi: 10.1016/j.gore.2019.100532. eCollection 2020 Feb. PMID: 31934607; PMCID: PMC6951478.
Copy Download .nbib Format: NLM
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.

Clinical cancer research : an official journal of the American Association for Cancer Research

Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK.
PMID: 33766814
Clin Cancer Res. 2021 May 15;27(10):2734-2741. doi: 10.1158/1078-0432.CCR-20-4618. Epub 2021 Mar 25.

PURPOSE: This surgical window of opportunity (window) study assessed the short-term effect of medroxyprogesterone acetate (MPA) alone versus MPA plus the histone deacetylase (HDAC) inhibitor entinostat on regulation of progesterone receptor (PR) in women with newly diagnosed endometrioid endometrial...

Cite
Duska LR, Filiaci VL, Walker JL, et al. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021;27(10):2734-2741doi: 10.1158/1078-0432.CCR-20-4618.
Duska, L. R., Filiaci, V. L., Walker, J. L., Holman, L. L., Hill, E. K., Moore, R. G., Ring, K. L., Pearl, M. L., Muller, C. Y., Kushnir, C. L., Lankes, H. A., Samuelson, M. I., Carrick, K. S., Rajan, A., Rodgers, W. H., Kohn, E. C., Piekarz, R., & Leslie, K. K. (2021). A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2734-2741. https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska, Linda R, et al. "A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2734-2741. doi: https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 May 15;27(10):2734-2741. doi: 10.1158/1078-0432.CCR-20-4618. Epub 2021 Mar 25. PMID: 33766814; PMCID: PMC8127359.
Copy Download .nbib Format: NLM
Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Merritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X, Sherman ME, Brinton LA, Yu H, Miller DS, Ramirez NC, Lankes HA, Birrer MJ, Huang GS, Gunter MJ.
PMID: 33622671
Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):719-726. doi: 10.1158/1055-9965.EPI-20-1613. Epub 2021 Feb 23.

BACKGROUND: The influence of sex hormone and insulin/insulin-like growth factor (IGF) axis signaling on endometrial cancer recurrence is unknown. We evaluated these pathways in a prospective cohort of Gynecologic Oncology Group (GOG)0210 trial endometrial adenocarcinoma patients.METHODS: Stage II-IV patients...

Cite
Merritt MA, Strickler HD, Hutson AD, et al. Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. Cancer Epidemiol Biomarkers Prev. 2021;30(4):719-726doi: 10.1158/1055-9965.EPI-20-1613.
Merritt, M. A., Strickler, H. D., Hutson, A. D., Einstein, M. H., Rohan, T. E., Xue, X., Sherman, M. E., Brinton, L. A., Yu, H., Miller, D. S., Ramirez, N. C., Lankes, H. A., Birrer, M. J., Huang, G. S., & Gunter, M. J. (2021). Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(4), 719-726. https://doi.org/10.1158/1055-9965.EPI-20-1613
Merritt, Melissa A, et al. "Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,4 (2021): 719-726. doi: https://doi.org/10.1158/1055-9965.EPI-20-1613
Merritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X, Sherman ME, Brinton LA, Yu H, Miller DS, Ramirez NC, Lankes HA, Birrer MJ, Huang GS, Gunter MJ. Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):719-726. doi: 10.1158/1055-9965.EPI-20-1613. Epub 2021 Feb 23. PMID: 33622671; PMCID: PMC8026669.
Copy Download .nbib Format: NLM
Genome-wide host methylation profiling of anal and cervical carcinoma.

PloS one

Siegel EM, Ajidahun A, Berglund A, Guerrero W, Eschrich S, Putney RM, Magliocco A, Riggs B, Winter K, Simko JP, Ajani JA, Guha C, Okawara GS, Abdalla I, Becker MJ, Pizzolato JF, Crane CH, Brown KD, Shibata D.
PMID: 34882728
PLoS One. 2021 Dec 09;16(12):e0260857. doi: 10.1371/journal.pone.0260857. eCollection 2021.

HPV infection results in changes in host gene methylation which, in turn, are thought to contribute to the neoplastic progression of HPV-associated cancers. The objective of this study was to identify joint and disease-specific genome-wide methylation changes in anal...

Cite
Siegel EM, Ajidahun A, Berglund A, et al. Genome-wide host methylation profiling of anal and cervical carcinoma. PLoS One. 2021;16(12):e0260857doi: 10.1371/journal.pone.0260857.
Siegel, E. M., Ajidahun, A., Berglund, A., Guerrero, W., Eschrich, S., Putney, R. M., Magliocco, A., Riggs, B., Winter, K., Simko, J. P., Ajani, J. A., Guha, C., Okawara, G. S., Abdalla, I., Becker, M. J., Pizzolato, J. F., Crane, C. H., Brown, K. D., & Shibata, D. (2021). Genome-wide host methylation profiling of anal and cervical carcinoma. PloS one, 16(12), e0260857. https://doi.org/10.1371/journal.pone.0260857
Siegel, Erin M, et al. "Genome-wide host methylation profiling of anal and cervical carcinoma." PloS one vol. 16,12 (2021): e0260857. doi: https://doi.org/10.1371/journal.pone.0260857
Siegel EM, Ajidahun A, Berglund A, Guerrero W, Eschrich S, Putney RM, Magliocco A, Riggs B, Winter K, Simko JP, Ajani JA, Guha C, Okawara GS, Abdalla I, Becker MJ, Pizzolato JF, Crane CH, Brown KD, Shibata D. Genome-wide host methylation profiling of anal and cervical carcinoma. PLoS One. 2021 Dec 09;16(12):e0260857. doi: 10.1371/journal.pone.0260857. eCollection 2021. PMID: 34882728; PMCID: PMC8659695.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries